argenx SE (ARGX) is a Biotechnology company in the Healthcare sector, currently trading at $828.35. It has a SharesGrow Score of 80/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ARGX = $973.18 (+17.5% from the current price, the stock appears undervalued). Analyst consensus target is ARGX = $1,027 (+23.9% upside).
Valuation: ARGX trades at a trailing Price-to-Earnings (P/E) of 42.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.36.
Financials: revenue is $4.2B, +122.4%/yr average growth. Net income is $1.3B, growing at +165.4%/yr. Net profit margin is 31.1% (strong). Gross margin is 89.1% (-3.7 pp trend).
Balance sheet: total debt is $83M against $7.3B equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 5.23 (strong liquidity). Debt-to-assets is 1%. Total assets: $8.7B.
Analyst outlook: 31 / 36 analysts rate ARGX as buy (86%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 52/100 (Partial), Growth 100/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 71/100 (Pass), Future 88/100 (Pass), Income 100/100 (Pass).
